Dr Cervantes, Scientific Chair of ESMO 2016, summarises the breaking research presented, and gives his highlights of the conference.
He discusses the trials of immune checkpoint modulators in multiple tumour sites, especially the data on lung cancer presented in Sundays press conference, and the progression of some therapies to first-line indications.
Dr Cervantes also considers novel combinations of molecules and modalities, many of which synergise with or magnify the impact of immunotherapy, and reflects on cell cycle modulation through CDK pathways as opening outcomes for women with metastatic breast cancer.
Overall, Dr Cervantes describes the research from this years conference as changing the way cancer therapy develops for clinicians, and most importantly for patients.
For all these and more, you can follow ecancer coverage of ESMO 2016 here.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.